Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.

Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.

Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC.

Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9. Review.

PMID:
15223016
4.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Kochenderfer JN, Rosenberg SA.

Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2. Review.

PMID:
23546520
5.

Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.

Marcus A, Eshhar Z.

Expert Opin Biol Ther. 2014 Jul;14(7):947-54. doi: 10.1517/14712598.2014.900540. Epub 2014 Mar 24. Review.

PMID:
24661086
6.

Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.

Xu XJ, Zhao HZ, Tang YM.

Leuk Lymphoma. 2013 Feb;54(2):255-60. doi: 10.3109/10428194.2012.715350. Epub 2012 Sep 8. Review.

PMID:
22897728
7.

Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.

Bouhassira DC, Thompson JJ, Davila ML.

Expert Opin Biol Ther. 2015 Mar;15(3):403-16. doi: 10.1517/14712598.2015.1014792. Epub 2015 Feb 9. Review.

8.

Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?

Davila ML, Brentjens R.

Hematol Oncol Clin North Am. 2013 Apr;27(2):341-53. doi: 10.1016/j.hoc.2012.12.004. Review.

9.
10.

Monoclonal antibodies in the treatment of chronic lymphoid leukemias.

Robak T.

Leuk Lymphoma. 2004 Feb;45(2):205-19. Review.

PMID:
15101704
11.

CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.

Gill S, Porter DL.

Expert Opin Biol Ther. 2014 Jan;14(1):37-49. doi: 10.1517/14712598.2014.860442. Epub 2013 Nov 21. Review.

PMID:
24261468
12.

CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.

Lorentzen CL, Straten PT.

Scand J Immunol. 2015 Oct;82(4):307-19. doi: 10.1111/sji.12331. Review.

PMID:
26099639
13.

Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.

Brentjens RJ, Curran KJ.

Hematology Am Soc Hematol Educ Program. 2012;2012:143-51. doi: 10.1182/asheducation-2012.1.143. Review.

PMID:
23233573
14.

Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.

Foster AE, Brenner MK, Dotti G.

Best Pract Res Clin Haematol. 2008 Sep;21(3):375-89. doi: 10.1016/j.beha.2008.08.002. Review.

15.

Chimeric antigen receptor modified T cell therapy for B cell malignancies.

Turtle CJ.

Int J Hematol. 2014 Feb;99(2):132-40. doi: 10.1007/s12185-013-1490-x. Epub 2013 Dec 14. Review.

PMID:
24338745
16.

CAR T cells: driving the road from the laboratory to the clinic.

Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE.

Immunol Rev. 2014 Jan;257(1):91-106. doi: 10.1111/imr.12126. Review.

PMID:
24329792
17.

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.

Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, Brentjens R.

Int J Hematol. 2014 Apr;99(4):361-71. doi: 10.1007/s12185-013-1479-5. Epub 2013 Dec 6. Review.

18.

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

Maude SL, Teachey DT, Porter DL, Grupp SA.

Blood. 2015 Jun 25;125(26):4017-23. doi: 10.1182/blood-2014-12-580068. Epub 2015 May 21. Review.

19.

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.

Singh N, Frey NV, Grupp SA, Maude SL.

Curr Treat Options Oncol. 2016 Jun;17(6):28. doi: 10.1007/s11864-016-0406-4. Review.

PMID:
27098534
20.

Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.

Zugmaier G, Klinger M, Schmidt M, Subklewe M.

Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Epub 2015 Apr 13. Review.

PMID:
25883042
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk